Week In Review: bioMérieux Acquires Majority Stake In China Diagnostics Company For $114 Million

French in vitro diagnostics company, bioMérieux (Paris: BIM), acquired a majority stake in Suzhou Hybiome Biomedical Engineering for $114 million. Hybiome specializes in automated immunoassay tests.